Ginkgo Bioworks Holdings Inc vs Hyatt Hotels Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M), while Hyatt Hotels Corporation trades at $160.27 (market cap $15.02B). The key difference: Hyatt Hotels Corporation is far larger — about 19.7× Ginkgo Bioworks Holdings Inc's market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Hyatt Hotels Corporation for 148 Days on average.
| DNA | H | |
|---|---|---|
Market Cap | $763.64M | $15.02B |
Volume | 3,204,177 | 842,340 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $202.09 |
52-Week Low | $5.48 | $135.42 |
Typical Hold Time | 7 Days | 148 Days |
Enterprise Value | $865.59M | $18.93B |
Dividend Yield | — | 0.38% |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
Hyatt Hotels (H) trades at $157.14, down 1.24% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows mixed fundamentals: revenue grew to $7.10B in 2025, but net income was a loss of $52M, and valuation ratios like a P/E of 194 appear elevated. Recent news highlights expansion efforts, including a loyalty collaboration with Delta Air Lines and new hotel openings, signaling growth initiatives amid operational challenges.
The outlook for H is cautious; analyst consensus is a Moderate Buy with a $197.77 price target, but high debt levels and volatile profitability pose risks. Upside depends on sustained revenue growth and margin improvement, while downside risks include economic sensitivity and execution delays in new projects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →